The MRZ reaction as a highly specific marker of multiple sclerosis

re-evaluation and structured review of the literature

Sven Jarius, P. Eichhorn, D. Franciotta, H. F. Petereit, Gulsen Akman-Demir, M. Wick, Brigitte Wildemann

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

It has long been known that the majority of patients with multiple sclerosis (MS) display an intrathecal, polyspecific humoral immune response to a broad panel of neurotropic viruses. This response has measles virus, rubella virus and varicella zoster virus as its most frequent constituents and is thus referred to as the MRZ reaction (MRZR). Re-evaluation of the specificity of MRZR as a marker of MS. Structured review of the existing English-, German- and Spanish-language literature on MRZR testing, with evaluation of MRZR in a cohort of 43 unselected patients with MS and other neurological diseases as a proof of principle. A positive MRZ reaction, defined as a positive intrathecal response to at least two of the three viral agents, was found in 78% of MS patients but only in 3% of the controls (p < 0.00001), corresponding to specificity of 97%. Median antibody index values were significantly lower in non-MS patients (measles, p < 0.0001; rubella, p < 0.006; varicella zoster, p < 0.02). The 30 identified original studies on MRZR reported results from 1478 individual MRZR tests. A positive MRZR was reported for 458/724 (63.3%) tests in patients with MS but only for 19/754 (2.5%) tests in control patients (p < 0.000001), corresponding to cumulative specificity of 97.5% (CI 95% 96–98.4), cumulative sensitivity of 63.3% (CI 95% 59.6–66.8) (or 67.4% [CI 95% 63.5–71.1] in the adult MS subgroup), a positive likelihood ratio of 25.1 (CI 95% 16–39.3) and a negative likelihood ratio of 0.38 (CI 95% 0.34–0.41). Of particular note, MRZR was absent in 52/53 (98.1%) patients with neuromyelitis optica or MOG-IgG-positive encephalomyelitis, two important differential diagnoses of MS. MRZR is the most specific laboratory marker of MS reported to date. If present, MRZR substantially increases the likelihood of the diagnosis of MS. Prospective and systematic studies on the diagnostic and prognostic impact of MRZR testing are highly warranted.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalJournal of Neurology
DOIs
Publication statusAccepted/In press - Dec 22 2016

Fingerprint

Multiple Sclerosis
Neuromyelitis Optica
Rubella virus
Encephalomyelitis
Measles virus
Human Herpesvirus 3
Chickenpox
Rubella
Herpes Zoster
Measles
Sclerosis
Humoral Immunity
Differential Diagnosis
Language
Immunoglobulin G
Biomarkers
Prospective Studies
Viruses
Antibodies

Keywords

  • Antibody index
  • Behçet’s disease
  • Cerebrospinal fluid
  • Connective tissue disorders
  • Herpes simplex virus
  • Measles virus
  • MRZ reaction
  • Multiple sclerosis
  • Neuroborreliosis Aquaporin-4-IgG-positive neuromyelitis optica MOG-IgG-positive encephalomyelitis
  • Rubella virus
  • Varicella zoster virus

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

The MRZ reaction as a highly specific marker of multiple sclerosis : re-evaluation and structured review of the literature. / Jarius, Sven; Eichhorn, P.; Franciotta, D.; Petereit, H. F.; Akman-Demir, Gulsen; Wick, M.; Wildemann, Brigitte.

In: Journal of Neurology, 22.12.2016, p. 1-14.

Research output: Contribution to journalArticle

Jarius, Sven ; Eichhorn, P. ; Franciotta, D. ; Petereit, H. F. ; Akman-Demir, Gulsen ; Wick, M. ; Wildemann, Brigitte. / The MRZ reaction as a highly specific marker of multiple sclerosis : re-evaluation and structured review of the literature. In: Journal of Neurology. 2016 ; pp. 1-14.
@article{f0eb8b8892f4408cba742393c36f0c35,
title = "The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature",
abstract = "It has long been known that the majority of patients with multiple sclerosis (MS) display an intrathecal, polyspecific humoral immune response to a broad panel of neurotropic viruses. This response has measles virus, rubella virus and varicella zoster virus as its most frequent constituents and is thus referred to as the MRZ reaction (MRZR). Re-evaluation of the specificity of MRZR as a marker of MS. Structured review of the existing English-, German- and Spanish-language literature on MRZR testing, with evaluation of MRZR in a cohort of 43 unselected patients with MS and other neurological diseases as a proof of principle. A positive MRZ reaction, defined as a positive intrathecal response to at least two of the three viral agents, was found in 78{\%} of MS patients but only in 3{\%} of the controls (p < 0.00001), corresponding to specificity of 97{\%}. Median antibody index values were significantly lower in non-MS patients (measles, p < 0.0001; rubella, p < 0.006; varicella zoster, p < 0.02). The 30 identified original studies on MRZR reported results from 1478 individual MRZR tests. A positive MRZR was reported for 458/724 (63.3{\%}) tests in patients with MS but only for 19/754 (2.5{\%}) tests in control patients (p < 0.000001), corresponding to cumulative specificity of 97.5{\%} (CI 95{\%} 96–98.4), cumulative sensitivity of 63.3{\%} (CI 95{\%} 59.6–66.8) (or 67.4{\%} [CI 95{\%} 63.5–71.1] in the adult MS subgroup), a positive likelihood ratio of 25.1 (CI 95{\%} 16–39.3) and a negative likelihood ratio of 0.38 (CI 95{\%} 0.34–0.41). Of particular note, MRZR was absent in 52/53 (98.1{\%}) patients with neuromyelitis optica or MOG-IgG-positive encephalomyelitis, two important differential diagnoses of MS. MRZR is the most specific laboratory marker of MS reported to date. If present, MRZR substantially increases the likelihood of the diagnosis of MS. Prospective and systematic studies on the diagnostic and prognostic impact of MRZR testing are highly warranted.",
keywords = "Antibody index, Beh{\cc}et’s disease, Cerebrospinal fluid, Connective tissue disorders, Herpes simplex virus, Measles virus, MRZ reaction, Multiple sclerosis, Neuroborreliosis Aquaporin-4-IgG-positive neuromyelitis optica MOG-IgG-positive encephalomyelitis, Rubella virus, Varicella zoster virus",
author = "Sven Jarius and P. Eichhorn and D. Franciotta and Petereit, {H. F.} and Gulsen Akman-Demir and M. Wick and Brigitte Wildemann",
year = "2016",
month = "12",
day = "22",
doi = "10.1007/s00415-016-8360-4",
language = "English",
pages = "1--14",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",

}

TY - JOUR

T1 - The MRZ reaction as a highly specific marker of multiple sclerosis

T2 - re-evaluation and structured review of the literature

AU - Jarius, Sven

AU - Eichhorn, P.

AU - Franciotta, D.

AU - Petereit, H. F.

AU - Akman-Demir, Gulsen

AU - Wick, M.

AU - Wildemann, Brigitte

PY - 2016/12/22

Y1 - 2016/12/22

N2 - It has long been known that the majority of patients with multiple sclerosis (MS) display an intrathecal, polyspecific humoral immune response to a broad panel of neurotropic viruses. This response has measles virus, rubella virus and varicella zoster virus as its most frequent constituents and is thus referred to as the MRZ reaction (MRZR). Re-evaluation of the specificity of MRZR as a marker of MS. Structured review of the existing English-, German- and Spanish-language literature on MRZR testing, with evaluation of MRZR in a cohort of 43 unselected patients with MS and other neurological diseases as a proof of principle. A positive MRZ reaction, defined as a positive intrathecal response to at least two of the three viral agents, was found in 78% of MS patients but only in 3% of the controls (p < 0.00001), corresponding to specificity of 97%. Median antibody index values were significantly lower in non-MS patients (measles, p < 0.0001; rubella, p < 0.006; varicella zoster, p < 0.02). The 30 identified original studies on MRZR reported results from 1478 individual MRZR tests. A positive MRZR was reported for 458/724 (63.3%) tests in patients with MS but only for 19/754 (2.5%) tests in control patients (p < 0.000001), corresponding to cumulative specificity of 97.5% (CI 95% 96–98.4), cumulative sensitivity of 63.3% (CI 95% 59.6–66.8) (or 67.4% [CI 95% 63.5–71.1] in the adult MS subgroup), a positive likelihood ratio of 25.1 (CI 95% 16–39.3) and a negative likelihood ratio of 0.38 (CI 95% 0.34–0.41). Of particular note, MRZR was absent in 52/53 (98.1%) patients with neuromyelitis optica or MOG-IgG-positive encephalomyelitis, two important differential diagnoses of MS. MRZR is the most specific laboratory marker of MS reported to date. If present, MRZR substantially increases the likelihood of the diagnosis of MS. Prospective and systematic studies on the diagnostic and prognostic impact of MRZR testing are highly warranted.

AB - It has long been known that the majority of patients with multiple sclerosis (MS) display an intrathecal, polyspecific humoral immune response to a broad panel of neurotropic viruses. This response has measles virus, rubella virus and varicella zoster virus as its most frequent constituents and is thus referred to as the MRZ reaction (MRZR). Re-evaluation of the specificity of MRZR as a marker of MS. Structured review of the existing English-, German- and Spanish-language literature on MRZR testing, with evaluation of MRZR in a cohort of 43 unselected patients with MS and other neurological diseases as a proof of principle. A positive MRZ reaction, defined as a positive intrathecal response to at least two of the three viral agents, was found in 78% of MS patients but only in 3% of the controls (p < 0.00001), corresponding to specificity of 97%. Median antibody index values were significantly lower in non-MS patients (measles, p < 0.0001; rubella, p < 0.006; varicella zoster, p < 0.02). The 30 identified original studies on MRZR reported results from 1478 individual MRZR tests. A positive MRZR was reported for 458/724 (63.3%) tests in patients with MS but only for 19/754 (2.5%) tests in control patients (p < 0.000001), corresponding to cumulative specificity of 97.5% (CI 95% 96–98.4), cumulative sensitivity of 63.3% (CI 95% 59.6–66.8) (or 67.4% [CI 95% 63.5–71.1] in the adult MS subgroup), a positive likelihood ratio of 25.1 (CI 95% 16–39.3) and a negative likelihood ratio of 0.38 (CI 95% 0.34–0.41). Of particular note, MRZR was absent in 52/53 (98.1%) patients with neuromyelitis optica or MOG-IgG-positive encephalomyelitis, two important differential diagnoses of MS. MRZR is the most specific laboratory marker of MS reported to date. If present, MRZR substantially increases the likelihood of the diagnosis of MS. Prospective and systematic studies on the diagnostic and prognostic impact of MRZR testing are highly warranted.

KW - Antibody index

KW - Behçet’s disease

KW - Cerebrospinal fluid

KW - Connective tissue disorders

KW - Herpes simplex virus

KW - Measles virus

KW - MRZ reaction

KW - Multiple sclerosis

KW - Neuroborreliosis Aquaporin-4-IgG-positive neuromyelitis optica MOG-IgG-positive encephalomyelitis

KW - Rubella virus

KW - Varicella zoster virus

UR - http://www.scopus.com/inward/record.url?scp=85006844248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006844248&partnerID=8YFLogxK

U2 - 10.1007/s00415-016-8360-4

DO - 10.1007/s00415-016-8360-4

M3 - Article

SP - 1

EP - 14

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -